Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines.

Abstract

Sorafenib is an orally administered multikinase inhibitor that exhibits anti-angiogenic and anti-tumor activity. Sorafenib is also known to bind to protein (>99.5%), suggesting protein binding may be involved in sorafenib pharmacokinetic variability. Albumin is a major drug-binding protein. In this study, we examined the effect of albumin on sorafenib… (More)

Topics

  • Presentations referencing similar topics